title: Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia.
abstract: OBJECTIVE
  To investigate whether cilostazol reduces restenosis and revascularization after infrapopliteal angioplasty.
  
  
  METHODS
  This study was a retrospective analysis of a multicenter prospective registry.
  
  
  METHODS
  Between February and April 2011, 63 patients (68 limbs, 101 lesions) with critical limb ischemia (CLI) were enrolled. Of these, 32 were cilostazol treated and 31 were the non-cilostazol-treated group. Outcome measures were binary restenosis by angiogram, reocclusion, target lesion revascularization (TLR), limb salvage rate and complete wound healing at 3 months.
  
  
  RESULTS
  Procedural success was obtained in all patients. The backgrounds and lesion characteristics of patients with isolated tibial artery disease and CLI did not differ significantly between the two groups. In a lesion-based analysis, binary restenosis and reocclusion were significantly lower in the cilostazol group than in the non-cilostazol group (56.8% vs. 86.0%; p = 0.015, 20.5% vs. 43.6%; p = 0.015, respectively). The TLR was also significantly lower in the cilostazol group (27.5% vs. 52.8%, p = 0.014). After adjustment for covariables, cilostazol was found to be associated with reduced angiographic restenosis, reocclusion and TLR rates in CLI patients at 3 months after infrapopliteal angioplasty. However, it remained unclear whether cilostazol was also associated with improved clinical outcomes.
  
  
  CONCLUSIONS
  Cilostazol may be associated with reduced restenosis, reocclusion and clinically driven TLR at 3 months after infrapopliteal angioplasty.
authors.affiliation: Kokura Memorial Hospital, Department of Cardiology, 3-2-1 Asano, Kokurakita-ku, Kitakyushu 802-0001, Japan. soga@circulation.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Soga
authors.forename: O
authors.initials: O
authors.lastname: Iida
authors.forename: D
authors.initials: D
authors.lastname: Kawasaki
authors.forename: K
authors.initials: K
authors.lastname: Hirano
authors.forename: T
authors.initials: T
authors.lastname: Yamaoka
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000800:Angioplasty, Balloon / Q000009:adverse effects / Q000401:mortality; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D000077407:Cilostazol; D003251:Constriction, Pathologic; D005260:Female; D006801:Humans; D007511:Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D007564:Japan; D023821:Limb Salvage; D016015:Logistic Models; D008297:Male; D058729:Peripheral Arterial Disease / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D011150:Popliteal Artery / Q000000981:diagnostic imaging / Q000187:drug effects*; D011859:Radiography; D012042:Registries; D012189:Retrospective Studies; D055502:Secondary Prevention; D013777:Tetrazoles / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects
chemical_list: D002317:Cardiovascular Agents; D013777:Tetrazoles; D000077407:Cilostazol